Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview with Lenka Francišković
Read the interview with Lenka Francišković, Quality Management, Head of Processes and Products Quality, Belupo
- Which Cost of Quality-related approaches and methodologies do you consider to be the best?
Cost of quality can be divided into the cost of good quality and the cost of poor quality. As it is too much of an effort to be able to calculate both costs, it is beneficial to calculate the cost of poor quality. By looking into the cost of poor quality, one is able to see where improvements are possible.
- From your experience, what can the impact of the cost of poor quality be?
It is very difficult to assume the impact of the cost of poor quality if you do not start collecting information on the cost of poor quality. It is only when the company decides to collect information on poor quality that many hidden situations are revealed and the actual cost and impact of poor quality is highlighted. There are still costs that are not accounted for such as the cost of market loss as a result of bad quality, the cost of reputation as a company and so on.
- How long have you applied the Cost of Quality methodology in Belupo? What are the main improvements you've achieved so far?
For several years, we have been looking into the cost of poor quality. The main achievement reached by this exercise is that the culture of doing something right the first time is understood by personnel. This changed the company’s culture of redoing a process because an actual cost can be calculated and the losses are known; therefore, the avoidance of such an event is built into the culture more and more with time.
- What is your biggest expectation for the upcoming conference?
I am curious to hear if any of the present companies are calculating the cost of poor quality and what their experiences are. And generally speaking, I am curious to touch upon several quality management topics with professionals from Russian and EU companies such as change control implementation and the filing of variations to Russian agencies. Besides, I learned the Russian language throughout my schooling and I would like to implement it in a real environment.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.